PROPHASE LABS INC. - COMMON STOCK

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

25 Aug 2023 12:27:23 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

18 Aug 2023 13:01:11 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

17 Aug 2023 08:47:26 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

16 Aug 2023 08:45:05 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

15 Aug 2023 09:36:33 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

14 Aug 2023 08:45:04 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

11 Aug 2023 10:12:54 By NetDania Notify

NetDania - New 12 months Low: PROPHASE LABS INC. - COMMON STOCK

10 Aug 2023 10:04:31 By NetDania Notify

ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.

10 Aug 2023 09:40:00 By Nasdaq GlobeNewswire

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

10 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time

02 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Navidea Biopharmaceuticals Rejects ProPhase Labs Offer To Acquire Certain Assets of Navidea

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ProPhase Labs Inc. Sets the Course for Expansion into the MENA Region with Cutting-Edge Genomic and Diagnostics Technologies

22 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023

11 May 2023 07:00:02 By Nasdaq GlobeNewswire

ProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology Programs

08 May 2023 07:30:00 By Nasdaq GlobeNewswire

ProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern Time

04 May 2023 07:30:01 By Nasdaq GlobeNewswire

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers

03 May 2023 07:30:00 By Nasdaq GlobeNewswire